Abstract
In adipose tissue, the primary physiological function of insulin is the suppression of lipolysis, the hydrolysis of stored fat. Mechanistically, insulin suppresses lipolysis both in transcriptional and post-transcriptional levels. Insulin signaling acutely inhibits beta-adrenergic signaling by decreasing intracellular cyclic AMP levels and the rate of lipolysis. Insulin also suppresses lipolysis by down-regulating the expression of the rate-limiting lipolytic enzyme, adipose triglyceride lipase or ATGL. In insulin resistance and type 2 diabetes, insulin mediated attenuation of lipolysis is impaired leading to an increased rate of lipolysis and increased release of free fatty acids (FFA) in the circulation. This is one of the potential mechanisms behind the development of hyperlipidemia and subsequent metabolic abnormalities in type 2 diabetes. In this article, we focus on the recent findings that highlight distinct molecular mechanisms by which insulin action is mediated and possible implications of the deregulation of these pathways in the pathophysiological context.
Keywords: ATGL, Gene expression, Insulin, Lipolysis, Type 2 diabetes, Beta-adrenergic signaling, Free fatty acids, Glucose transporter 4 (GLUT4), Hormone sensitive lipase (HSL)
Current Diabetes Reviews
Title: Adipose Triglyceride Lipase: A New Target in the Regulation of Lipolysis by Insulin
Volume: 7 Issue: 4
Author(s): Partha Chakrabarti and Konstantin V. Kandror
Affiliation:
Keywords: ATGL, Gene expression, Insulin, Lipolysis, Type 2 diabetes, Beta-adrenergic signaling, Free fatty acids, Glucose transporter 4 (GLUT4), Hormone sensitive lipase (HSL)
Abstract: In adipose tissue, the primary physiological function of insulin is the suppression of lipolysis, the hydrolysis of stored fat. Mechanistically, insulin suppresses lipolysis both in transcriptional and post-transcriptional levels. Insulin signaling acutely inhibits beta-adrenergic signaling by decreasing intracellular cyclic AMP levels and the rate of lipolysis. Insulin also suppresses lipolysis by down-regulating the expression of the rate-limiting lipolytic enzyme, adipose triglyceride lipase or ATGL. In insulin resistance and type 2 diabetes, insulin mediated attenuation of lipolysis is impaired leading to an increased rate of lipolysis and increased release of free fatty acids (FFA) in the circulation. This is one of the potential mechanisms behind the development of hyperlipidemia and subsequent metabolic abnormalities in type 2 diabetes. In this article, we focus on the recent findings that highlight distinct molecular mechanisms by which insulin action is mediated and possible implications of the deregulation of these pathways in the pathophysiological context.
Export Options
About this article
Cite this article as:
Chakrabarti Partha and V. Kandror Konstantin, Adipose Triglyceride Lipase: A New Target in the Regulation of Lipolysis by Insulin, Current Diabetes Reviews 2011; 7 (4) . https://dx.doi.org/10.2174/157339911796397866
DOI https://dx.doi.org/10.2174/157339911796397866 |
Print ISSN 1573-3998 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6417 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Donor-transmitted Anterior Myocardial Ischaemia in a Teenager: How to Proceed?
New Emirates Medical Journal The Fundamental Role of Stress Echo in Evaluating Coronary Artery Disease in Specific Patient Populations
Current Vascular Pharmacology Induced Pluripotent Stem Cells in Regenerative Medicine and Disease Modeling
Current Stem Cell Research & Therapy Prader-Willi Syndrome: Clinical Genetics and Diagnostic Aspects with Treatment Approaches
Current Pediatric Reviews Cardiovascular Toxicity from the Perspective of Oxidative Stress, Electron Transfer, and Prevention by Antioxidants
Current Vascular Pharmacology Free Radicals and Antioxidants: How to Reestablish Redox Homeostasis in Chronic Diseases?
Current Medicinal Chemistry Pharmacological Modulations of the Renin-Angiotensin-Aldosterone System in Human Congestive Heart Failure: Effects on Peripheral Vascular Endothelial Function
Current Vascular Pharmacology Gene Therapy in Liver Diseases: State-of-the-Art and Future Perspectives
Current Gene Therapy FoxO1 Inhibitors: The Future Medicine for Metabolic Disorders?
Current Diabetes Reviews Thrombolytic Treatment of Cardiac Myxoma-Induced Ischemic Stroke: A Review
Current Drug Safety Inhibition of Interleukin-1 in the Treatment of Selected Cardiovascular Complications
Current Reviews in Clinical and Experimental Pharmacology The Role of Transcription Factors in the Formation of an Arrhythmogenic Substrate in Congestive Human Heart Failure
Current Medicinal Chemistry Fatty Acids - Induced Lipotoxicity and Inflammation
Current Drug Metabolism Cardiac Workup of Ischemic Stroke
Current Cardiology Reviews The Ryanodine Receptor: A Pivotal Ca2+ Regulatory Protein and Potential Therapeutic Drug Target
Current Drug Targets The HGF/c-Met Receptor System Under Pathological Conditions
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Cardiac Biomarkers in Stroke, Alzheimer’s Disease, and Other Dementia. Are They of Use? A Brief Overview of Data from Recent Investigations
CNS & Neurological Disorders - Drug Targets A Brief History of ‘Lone’ Atrial Fibrillation: From ‘A Peculiar Pulse Irregularity’ to a Modern Public Health Concern
Current Pharmaceutical Design Biomarkers of Atrial Fibrillation in Metabolic Syndrome
Current Medicinal Chemistry Modular Nanotransporters for Targeted Intracellular Delivery of Drugs: Folate Receptors as Potential Targets
Current Pharmaceutical Design